Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. have entered into a definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan.
David Renzi, President and CEO of Carbylan stated: “We are optimistic that KalVista’s pipeline and strong leadership team, together with the combined company’s cash resources, will enable the company to reach significant milestones in KalVista’s pipeline.”
Andrew Crockett, KalVista’s CEO said: “This transaction allows us to continue the development of our potentially best-in-class plasma kallikrein inhibitor platform, and rapidly advance our programs in HAE, bringing much-needed treatments to patients. We are in a very strong position to drive the growth of the combined company, and achieve the full potential of our therapeutic pipeline.”
The proposed transaction is expected to close late in the third quarter or early in the fourth quarter of 2016.